请输入您要查询的百科知识：

　

词条 List of therapeutic monoclonal antibodies
释义

  1. References

{{Dynamic list}}

This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

The abbreviations in the column Type are as follows:

  • mab: whole monoclonal antibody
  • Fab: fragment, antigen-binding (one arm)
    • F(ab')2: fragment, antigen-binding, including hinge region (both arms)
    • Fab': fragment, antigen-binding, including hinge region (one arm)
  • Variable fragments:
    • scFv: single-chain variable fragment
    • di-scFv: dimeric single-chain variable fragment
    • sdAb: single-domain antibody
  • Bispecific monoclonal antibodies:
    • 3funct: trifunctional antibody
    • BiTE: bi-specific T-cell engager

This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA approved therapeutic monoclonal antibodies in the Monoclonal antibody therapy page.

Approved Use
3F8 mab mouse GD2 ganglioside neuroblastoma
8H9[1] mab mouse B7-H3 neuroblastoma, sarcoma, metastatic brain cancers
Abagovomab[2] mab mouse CA-125 (imitation) ovarian cancer
Abciximab ReoPro Fab chimeric CD41 (integrin alpha-IIb)Y platelet aggregation inhibitor
Abituzumab[3] mab humanized CD51 cancer
Abrezekimab[4] Fab humanized interleukin 13 ?
Abrilumab mab human integrin α4β7 inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab mab human Clostridium difficile Clostridium difficile colitis
Adalimumab Humira mab human TNF-αY Rheumatoid arthritis, Crohn's disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hemolytic disease of the newborn
Adecatumumab[5] mab human EpCAM prostate and breast cancer
Atidortoxumab[6] mab human Staphylococcus aureus alpha toxin ?
Aducanumab mab human beta-amyloid Alzheimer's disease
Afasevikumab[7] mab human IL17A and IL17F multiple sclerosis
Afelimomab F(ab')2 mouse TNF-α sepsis
Alacizumab pegol[8] F(ab')2 humanized VEGFR2 cancer
Alemtuzumab[9] Lemtrada, Campath mab humanized CD52Y Multiple sclerosis
Alirocumab Praluent mab human PCSK9Y hypercholesterolemia
Altumomab pentetate Hybri-ceaker mab mouse CEA colorectal cancer (diagnosis)
Amatuximab mab chimeric mesothelin cancer
Anatumomab mafenatox Fab mouse TAG-72 non-small cell lung carcinoma
Andecaliximab mab chimeric gelatinase B gastric cancer or gastroesophageal junction adenocarcinoma
Anetumab ravtansine[3] mab human MSLN cancer
Anifrolumab mab human interferon α/β receptor systemic lupus erythematosus
Anrukinzumab[8] (= IMA-638)[12] mab humanized IL-13 asthma
Apolizumab[13] mab humanized HLA-DR ? hematological cancers
Aprutumab ixadotin[14] mab human FGFR2 ?
Arcitumomab CEA-Scan Fab' mouse CEA gastrointestinal cancers (diagnosis)
Ascrinvacumab mab human activin receptor-like kinase 1 cancer
Aselizumab[15] mab humanized L-selectin (CD62L) severely injured patients
Atezolizumab[16] Tecentriq mab humanized PD-L1Y cancer
Atinumab[17] mab human RTN4 ?
Atorolimumab mab human Rhesus factordate=November 2009}}
Avelumab[7] Bavencio mab human PD-L1Y cancer
Azintuxizumab vedotin[19] mab chimeric/humanized CD319 cancer
Bapineuzumab[20] mab humanized beta amyloid Alzheimer's disease
Basiliximab Simulect mab chimeric CD25 (α chain of IL-2 receptor)Y prevention of organ transplant rejections
Bavituximab[2] mab chimeric phosphatidylserine cancer, viral infections
BCD-100 ? human PD-1 melanoma
Bectumomab LymphoScan Fab' mouse CD22 non-Hodgkin's lymphoma (detection)
Begelomab[22] mab mouse DPP4 ?
Belantamab mafodotin[4] mab humanized BCMA cancer
Belimumab Benlysta mab human BAFFY non-Hodgkin lymphoma etc.
Bemarituzumab[6] mab humanized FGFR2 gastric cancer or gastroesophageal junction adenocarcinoma
Benralizumab Fasenra mab humanized CD125Y asthma
Berlimatoxumab[6] mab human Staphylococcus aureus bi-component leukocidin ?
Bermekimab Xilonix mab human IL1A colorectal cancer
Bersanlimab[4] mab human ICAM-1 ?
Bertilimumab[15] mab human CCL11 (eotaxin-1) severe allergic disorders
Besilesomab[28] Scintimun mab mouse CEA-related antigen inflammatory lesions and metastases (detection)
Bevacizumab[9] Avastin mab humanized VEGF-AY metastatic cancer, retinopathy of prematurity
Bezlotoxumab Zinplava mab human Clostridium difficileY Clostridium difficile colitis
Biciromab FibriScint Fab' mouse fibrin II, beta chain thromboembolism (diagnosis)
Bimagrumab[30] mab human ACVR2B myostatin inhibitor
Bimekizumab[31] mab humanized IL 17A and IL 17F ankylosing spondylitis, psoriasis
Birtamimab mab chimeric serum amyloid A protein amyloidosis
Bivatuzumab mertansine mab humanized CD44 v6 squamous cell carcinoma
Bleselumab[7] mab human CD40 organ transplant rejection
Blinatumomab Blincyto BiTE mouse CD19Y pre-B ALL (CD19+)
Blontuvetmab[33] Blontress mab veterinary CD20
Blosozumab[34] mab humanized SOST osteoporosis
Bococizumab mab humanized neural apoptosis-regulated proteinase 1 dyslipidemia
Brazikumab[35] mab human IL23 Crohn's disease
Brentuximab vedotin Adcentris mab chimeric CD30 (TNFRSF8)Y Hodgkin lymphomaAnaplastic large-cell lymphoma
Briakinumab mab human IL-12, IL-23 psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab Siliz mab human IL-17YPlaque psoriasis
Brolucizumab[16] scFv humanized VEGFA wet age-related macular degeneration
Brontictuzumab[22] mab humanized Notch 1 cancer
Burosumab[35] Crysvita mab human FGF 23Y X-linked hypophosphatemia
Cabiralizumab[33] mab humanized CSF1R metastatic pancreatic cancer
Camidanlumab tesirine[6] mab human CD25 B-cell Hodgkin’s lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia
Camrelizumab[14] mab humanized PD-1 hepatocellular carcinoma
Canakinumab[42] Ilaris mab human IL-1Y Cryopyrin-associated periodic syndrome
Cantuzumab mertansine mab humanized mucin CanAg colorectal cancer etc.
Cantuzumab ravtansine[34] mab humanized MUC1 cancers
Caplacizumab[44] Cablivi sdAb humanized VWFY thrombotic thrombocytopenic purpura, thrombosis
Capromab pendetide Prostascint mab mouse prostatic carcinoma cellsY prostate cancer (detection)
Carlumab mab human MCP-1 oncology/immune indications
Carotuximab[33] mab chimeric endoglin angiosarcoma
Catumaxomab[20] Removab 3funct rat/mouse hybrid EpCAM, CD3Y ovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugate mab humanized Lewis-Y antigen cancer
Cedelizumab mab humanized CD4 prevention of organ transplant rejections, treatment of autoimmune diseases
Cemiplimab Libtayo mab human PCDC1Y cutaneous squamous cell carcinoma
Cergutuzumab amunaleukin[7] mab humanized IL2 cancer
Certolizumab pegol[5] Cimzia Fab' humanized TNF-αY Crohn's disease, Rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis
Cetrelimab[4] mab human PD-1 cancer
Cetuximab Erbitux mab chimeric EGFRY metastatic colorectal cancer and head and neck cancer
Cibisatamab[4] mab humanized CEACAM5 cancer
Cirmtuzumab ? humanized ROR1 chronic lymphocytic leukemia
Citatuzumab bogatox[51] Fab humanized EpCAM ovarian cancer and other solid tumors
Cixutumumab mab human IGF-1 receptor (CD221)Y solid tumors
Clazakizumab[52] mab humanized IL6 rheumatoid arthritis
Clenoliximab mab chimeric CD4 rheumatoid arthritis
Clivatuzumab tetraxetan hPAM4-Cide mab humanized MUC1 pancreatic cancer
Codrituzumab[3] mab humanized glypican 3 cancer
Cofetuzumab pelidotin[6] mab humanized PTK7 cancer
Coltuximab ravtansine[3] mab chimeric CD19 cancer
Conatumumab[51] mab human TRAIL-R2 cancer
Concizumab[30] mab humanized TFPI bleeding
Cosfroviximab[19] ZMapp mab chimeric ebolavirus glycoprotein Ebola virus
Crenezumab mab humanized 1-40-β-amyloid Alzheimer's disease
Crizanlizumab[14] mab humanized selectin P sickle-cell disease
Crotedumab[33] mab human GCGR diabetes
CR6261 mab human Influenza A hemagglutinin infectious disease/influenza A
Cusatuzumab[4] mab humanized CD70 cancer
Dacetuzumab[8] mab humanized CD40 hematologic cancers
Daclizumab Zenapax mab humanized CD25 (α chain of IL-2 receptor)Y prevention of organ transplant rejections, multiple sclerosis
Dalotuzumab mab humanized IGF-1 receptor (CD221) cancer etc.
Dapirolizumab pegol[31] mab humanized CD154 (CD40L) ?
Daratumumab[64] Darzalex mab human CD38Y Multiple myeloma
Dectrekumab[16] mab human IL-13 ?
Demcizumab mab humanized DLL4 cancer
Denintuzumab mafodotin[22] mab humanized CD19 cancer
Denosumab[67] Prolia mab human RANKLY osteoporosis, bone metastases etc.
Depatuxizumab mafodotin[35] mab chimeric/humanized EGFR glioblastoma
Derlotuximab biotin mab chimeric histone complex recurrent glioblastoma multiforme
Detumomab mab mouse B-lymphoma cell lymphoma
Dezamizumab[14] mab humanized serum amyloid P component ?
Dinutuximab Unituxin mab chimeric GD2 gangliosideY neuroblastoma
Diridavumab mab human hemagglutinin influenza A
Domagrozumab[33] mab humanized GDF-8 Duchenne muscular dystrophy
Dorlimomab aritox[71] F(ab')2 mouse ? ?
Dostarlimab[72] mab humanized PCDP1 cancer
Drozitumab mab human DR5 cancer etc.
DS-8201 ? humanized HER2 gastric or gastroesophageal junction adenocarcinoma
Duligotuzumab[73] mab humanized ERBB3 (HER3) testicular cancer
Dupilumab Dupixent mab human IL-4RαY atopic diseases
Durvalumab Imfinzi mab human PD-L1Y cancer
Dusigitumab mab human ILGF2 B-cell malignancies
Duvortuxizumab[19] scFv chimeric/humanized CD19, CD3E cancer
Ecromeximab[13] mab chimeric GD3 ganglioside malignant melanoma
Eculizumab[13] Soliris mab humanized C5Y paroxysmal nocturnal hemoglobinuria, atypical HUS
Edobacomab mab mouse endotoxin sepsis caused by Gram-negative bacteria
Edrecolomab Panorex mab mouse EpCAM colorectal carcinoma
Efalizumab[77] Raptiva mab humanized LFA-1 (CD11a) psoriasis (blocks T-cell migration)
Efungumab[2] Mycograb scFv human Hsp90 invasive Candida infection
Eldelumab mab human interferon gamma-induced protein Crohn's disease, ulcerative colitis
Elezanumab[14] mab human RGMA spinal cord injury and multiple sclerosis
Elgemtumab[16] mab human ERBB3 (HER3) cancer
Elotuzumab Empliciti mab humanized SLAMF7Y multiple myeloma
Elsilimomab mab mouse IL-6 ?
Emactuzumab[22] mab humanized CSF1R cancer
Emapalumab Gamifant mab human interferon gammaY hemophagocytic lymphohistiocytosis
Emibetuzumab mab humanized HHGFR cancer
Emicizumab[7] Hemlibra mab humanized activated F9, F10Y haemophilia A
Enapotamab vedotin[4] mab human AXL cancer
Enavatuzumab mab humanized TWEAK receptor cancer etc.
Enfortumab vedotin mab human nectin-4 urothelial cancer
Enlimomab pegol[84] mab mouse ICAM-1 (CD54) ?
Enoblituzumab mab humanized CD276 cancer
Enokizumab mab humanized IL9 asthma
Enoticumab[73] mab human DLL4 ?
Ensituximab mab chimeric 5AC cancer
Epitumomab cituxetan mab mouse episialin ?
Epratuzumab mab humanized CD22 cancer, SLE
Eptinezumab mab humanized calcitonin gene-related peptide migraine
Erenumab[35] Aimovig mab human CGRPY migraine
Erlizumab[88] F(ab')2 humanized ITGB2 (CD18) heart attack, stroke, traumatic shock
Ertumaxomab[20] Rexomun 3funct rat/mouse hybrid HER2/neu, CD3Y breast cancer etc.
Etaracizumab Abegrin mab humanized integrin αvβ3Y melanoma, prostate cancer, ovarian cancer etc.
Etigilimab[4] mab humanized TIGIT ?
Etrolizumab mab humanized integrin β7 inflammatory bowel disease
Evinacumab mab human angiopoietin 3 dyslipidemia
Evolocumab[30] Repatha mab human PCSK9Y hypercholesterolemia
Exbivirumab[92] mab human hepatitis B surface antigen hepatitis B
Fanolesomab[93] NeutroSpec mab mouse CD15 appendicitis (diagnosis)
Faralimomab mab mouse interferon receptor ?
Faricimab[4] mab humanized VEGF-A and Ang-2 angiogenesis, ocular vascular diseases
Farletuzumab mab humanized folate receptor 1 ovarian cancer
Fasinumab mab human HNGF acute sciatic pain
FBTA05[1][2] Lymphomun 3funct rat/mouse hybrid CD20 chronic lymphocytic leukaemia
Felvizumab mab humanized respiratory syncytial virus respiratory syncytial virus infection
Fezakinumab[97][98] mab human IL-22 rheumatoid arthritis, psoriasis
Fibatuzumab[7] mab humanized ephrin receptor A3 ?
Ficlatuzumab mab humanized HGF cancer etc.
Figitumumab mab human IGF-1 receptor (CD221) adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab[22] mab human influenza A virus hemagglutinin ?
Flanvotumab mab human TYRP1 (glycoprotein 75) melanoma
Fletikumab mab human IL 20 rheumatoid arthritis
Flotetuzumab[4] di-scFv humanized IL 3 receptor hematological malignancies
Fontolizumab[13] HuZAF mab humanized IFN-γ Crohn's disease etc.
Foralumab[103] mab human CD3 epsilon ?
Foravirumab[51] mab human rabies virus glycoprotein rabies (prophylaxis)
Fremanezumab[14] Ajovy mab humanized calcitonin gene-related peptide alphaY migraine and cluster headache
Fresolimumab mab human TGF-β idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Frovocimab[72] mab humanized PCSK9 hypercholesterolemia
Frunevetmab[19] mab veterinary NGF ?
Fulranumab mab human NGF pain
Futuximab[73] mab chimeric EGFR cancer
Galcanezumab[33] Emgality mab humanized calcitoninY migraine
Galiximab mab chimeric CD80 B-cell lymphoma
Gancotamab scFv human HER2/neu cancer
Ganitumab mab human IGF-1 receptor (CD221) cancer
Gantenerumab[42] mab human beta amyloid Alzheimer's disease
Gatipotuzumab[19] mab humanized MUC1 cancer
Gavilimomab[88] mab mouse CD147 (basigin) graft versus host disease
Gedivumab[19] mab human hemagglutinin HA ?
Gemtuzumab ozogamicin Mylotarg mab humanized CD33Y acute myelogenous leukemia
Gevokizumab mab humanized IL-1β diabetes etc.
Gilvetmab[19] mab veterinary PCDC1 ?
Gimsilumab[6] mab human CSF2 rheumatoid arthritis
Girentuximab[64] Rencarex mab chimeric carbonic anhydrase 9 (CA-IX)Y clear cell renal cell carcinoma[3]
Glembatumumab vedotin[118][119] mab human GPNMB melanoma, breast cancer
Golimumab[92] Simponi mab human TNF-αY rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab mab chimeric CD23 (IgE receptor) allergic asthma
Gosuranemab mab humanized tau protein progressive supranuclear palsy
Guselkumab Tremfya mab human IL23Y psoriasis
Ianalumab[6] mab human BAFF-R autoimmune hepatitis
Ibalizumab[42] Trogarzo mab humanized CD4Y HIV infection
IBI308 ? human PD-1 squamous cell non-small cell lung cancer
Ibritumomab tiuxetan Zevalin mab mouse CD20Y non-Hodgkin's lymphoma
Icrucumab mab human VEGFR-1 cancer etc.
Idarucizumab[3] Praxbind mab humanized dabigatranY reversal of anticoagulant effects of dabigatran
Ifabotuzumab[14] mab humanized EPHA3 ?
Igovomab Indimacis-125 F(ab')2 mouse CA-125 ovarian cancer (diagnosis)
Iladatuzumab vedotin[6] mab humanized CD97B cancer
IMAB362 mab human CLDN18.2 gastrointestinal adenocarcinomas and pancreatic tumor
Imalumab[22] mab human MIF cancer
Imaprelimab[4] mab humanized MCAM ?
Imciromab Myoscint mab mouse cardiac myosinY cardiac imaging
Imgatuzumab[73] mab humanized EGFR cancer
Inclacumab[44] mab human selectin P cardiovascular disease
Indatuximab ravtansine[34] mab chimeric SDC1 cancer
Indusatumab vedotin[16] mab human GUCY2C cancer
Inebilizumab[7] mab humanized CD19 cancer, systemic sclerosis, multiple sclerosis
Infliximab Remicade mab chimeric TNF-αY rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[133][134] mab human CD51 solid tumors (prostate cancer, melanoma)
Inolimomab mab mouse CD25 (α chain of IL-2 receptor) graft versus host disease
Inotuzumab ozogamicin[28] Besponsa mab humanized CD22Y ALL
Ipilimumab[67] Yervoy mab human CD152Y melanoma
Iomab-B ? mouse CD45 ablation of bone marrow
Iratumumab[67] mab human CD30 (TNFRSF8) Hodgkin's lymphoma
Isatuximab mab chimeric CD38 multiple myeloma
Iscalimab[4] mab human CD40 ?
Istiratumab[6] mab human IGF1R, CD221 advanced solid tumors
Itolizumab[103] Alzumab mab humanized CD6Y psoriasis
Ixekizumab Taltz mab humanized IL 17AY autoimmune diseases
Keliximab mab chimeric CD4 chronic asthma
Labetuzumab[77] CEA-Cide mab humanized CEA colorectal cancer
Lacnotuzumab[19] mab humanized CSF1, MCSF cancer
Ladiratuzumab vedotin[6] mab humanized LIV-1 cancer
Lampalizumab[73] Fab humanized CFD geographic atrophy secondary to age-related macular degeneration
Lanadelumab[33] Takhzyro mab human kallikreinY angioedema
Landogrozumab[7] mab humanized GDF-8 muscle wasting disorders
Laprituximab emtansine[33] mab chimeric EGFR ?
Larcaviximab[19] mab chimeric ebolavirus glycoprotein Ebola virus
Lebrikizumab mab humanized IL-13 asthma
Lemalesomab[88] mab mouse NCA-90 (granulocyte antigen) diagnostic agent
Lendalizumab[33] mab humanized C5 ?
Lenvervimab[4] mab humanized hepatitis B surfage antigen hepatitis B
Lenzilumab[22] mab human CSF2 chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia
Lerdelimumab[9] mab human TGF beta 2 reduction of scarring after glaucoma surgery
Leronlimab[4] mab humanized CCR5 ?
Lesofavumab[19] mab human hemagglutinin HA ?
Letolizumab[19] scFv humanized TRAP inflammatory diseases
Lexatumumab[2] mab human TRAIL-R2 cancer
Libivirumab[92] mab human hepatitis B surface antigen hepatitis B
Lifastuzumab vedotin mab humanized phosphate-sodium co-transporter cancer
Ligelizumab[73] mab humanized IGHE severe asthma and chronic spontaneous urticaria
Loncastuximab tesirine[6] mab chimeric CD19 cancer
Losatuxizumab vedotin[19] mab chimeric/humanized EGRF, ERBB1 HER1 cancer
Lilotomab satetraxetan[16] mab mouse CD37 cancer
Lintuzumab mab humanized CD33 cancer
Lirilumab[73] mab human KIR2D solid and hematological cancers
Lodelcizumab[30] mab humanized PCSK9 hypercholesterolemia
Lokivetmab[16] Cytopoint[4] mab veterinary Canis lupus familiaris IL31Y clinical signs of atopic dermatitis in dogs[4]
Lorvotuzumab mertansine mab humanized CD56 cancer
Lucatumumab[8] mab human CD40 multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol mab humanized CD28 autoimmune diseases
Lumiliximab[5] mab chimeric CD23 (IgE receptor) chronic lymphocytic leukemia
Lumretuzumab[22] mab humanized ERBB3 (HER3) cancer
Lupartumab amadotin[14] mab human LYPD3 ?
Lutikizumab[14] mab humanized interleukin 1 alpha ?
Mapatumumab[20] mab human TRAIL-R1 cancer
Margetuximab mab humanized HER2 breast cancer
Marstacimab mab human TFPI bleeding with hemophilia
Maslimomab ? mouse T-cell receptor
Mavrilimumab mab human GMCSF receptor α-chain rheumatoid arthritis
Matuzumab[15] mab humanized EGFR colorectal, lung and stomach cancer
Mepolizumab Bosatria mab humanized IL-5Y asthma and white blood cell diseases
Metelimumab[93] mab human TGF beta 1 systemic scleroderma
Milatuzumab[8] mab humanized CD74 multiple myeloma and other hematological malignancies
Minretumomab mab mouse TAG-72 tumor detection (and therapy?)
Mirikizumab[6] mab humanized IL23A psoriasis
Mirvetuximab soravtansine mab chimeric folate receptor alpha ovarian cancer
Mitumomab mab mouse GD3 ganglioside small cell lung carcinoma
Modotuximab mab chimeric EGFR extracellular domain III cancer
Mogamulizumab Poteligeo mab humanized CCR4Y adult T-cell leukemia/lymphoma
Monalizumab[7] mab humanized NKG2A rheumatoid arthritis, gynecologic malignancies, and other cancers
Morolimumab mab human Rhesus factor
Mosunetuzumab[6] mab humanized CD3E, MS4A1, CD20 cancer
Motavizumab[2] Numax mab humanized respiratory syncytial virus respiratory syncytial virus (prevention)
Moxetumomab pasudotox Lumoxiti mab mouse CD22Y hairy cell leukemia
Muromonab-CD3 Orthoclone OKT3 mab mouse CD3 prevention of organ transplant rejections
Nacolomab tafenatox Fab mouse C242 antigen colorectal cancer
Namilumab[17] mab human CSF2
Naptumomab estafenatox[182] Fab mouse 5T4 non-small cell lung carcinoma, renal cell carcinoma
Naratuximab emtansine[33] mab chimeric CD37
Narnatumab mab human MST1R (aka RON) cancer
Natalizumab Tysabri mab humanized integrin α4Y multiple sclerosis, Crohn's disease
Navicixizumab[33] mab chimeric/humanized DLL4 and VEGFA cancer
Navivumab[7] mab human influenza A virus hemagglutinin HA
Naxitamab ? humanized c-Met high-risk neuroblastoma and refractory osteomedullary disease
Nebacumab mab human endotoxin sepsis
Necitumumab[186] Portrazza mab human EGFRY non-small cell lung carcinoma
Nemolizumab[16] mab humanized IL31RA eczema[5]
NEOD001 ? humanized amyloid primary systemic amyloidosis
Nerelimomab mab mouse TNF-α ?
Nesvacumab mab human angiopoietin 2 cancer
Netakimab[4] mab chimeric interleukin 17A ?
Nimotuzumab[67][191] Theracim, Theraloc mab humanized EGFRY squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nirsevimab mab human RSVFR respiratory syncytial virus
Nivolumab Opdivo mab human PD-1Y cancer
Nofetumomab merpentan Verluma Fab mouse ? cancer (diagnosis)
Obiltoxaximab Anthim mab chimeric Bacillus anthracis anthraxY Bacillus anthracis spores
Obinutuzumab Gazyva mab humanized CD20YChronic lymphatic leukemia
Ocaratuzumab mab humanized CD20 cancer
Ocrelizumab[67] Ocrevus mab humanized CD20Y rheumatoid arthritis, lupus erythematosus etc.
Odulimomab mab mouse LFA-1 (CD11a) prevention of organ transplant rejections, immunological diseases
Ofatumumab[20] Arzerra mab human CD20Y chronic lymphocytic leukemia etc.
Olaratumab Lartruvo mab human PDGF-R αY cancer
Oleclumab[19] mab human 5'-nucleotidase pancreatic and colorectal cancer
Olendalizumab mab humanized complement C5a systemic lupus erythematosus, lupus nephritis, acute graft-versus-hose disease
Olokizumab[103] mab humanized IL6 rheumatoid arthritis
Omalizumab[88] Xolair mab humanized IgE Fc regionY allergic asthma
Omburtamab[72] mab mouse CD276 cancer
OMS721 ? human MASP-2 atypical hemolytic uremic syndrome
Onartuzumab Fab humanized human scatter factor receptor kinase cancer
Ontuxizumab mab chimeric/humanized TEM1 cancer
Onvatilimab[4] mab human VSIR ?
Opicinumab mab human LINGO-1 multiple sclerosis
Oportuzumab monatox[186] Vicinium scFv humanized EpCAM bladder cancer
Oregovomab[93] OvaRex mab mouse CA-125 ovarian cancer
Orticumab[73] mab human oxLDL
Otelixizumab[8] mab chimeric/humanized CD3 diabetes mellitus type 1
Otilimab mab human GMCSF osteoarthritis, rheumatoid arthritis
Otlertuzumab mab humanized CD37 cancer
Oxelumab mab human OX-40 asthma
Ozanezumab mab humanized NOGO-A ALS and multiple sclerosis
Ozoralizumab mab humanized TNF-α inflammation
Pagibaximab[20] mab chimeric lipoteichoic acid sepsis (Staphylococcus)
Palivizumab Synagis, Abbosynagis mab humanized F protein of respiratory syncytial virusY respiratory syncytial virus (prevention)
Pamrevlumab[7] mab human CTGF idiopathic pulmonary fibrosis (IPF), pancreatic cancer
Panitumumab[92] Vectibix mab human EGFRY colorectal cancer
Pankomab mab humanized tumor specific glycosylation of MUC1 ovarian cancer
Panobacumab[186] mab human Pseudomonas aeruginosa Pseudomonas aeruginosa infection
Parsatuzumab[73] mab human EGFL7 cancer
Pascolizumab[13] mab humanized IL-4 asthma
Pasotuxizumab[22] mab chimeric/humanized folate hydrolase cancer
Pateclizumab[34] mab humanized LTA TNF
Patritumab[44] mab human ERBB3 (HER3) cancer
PDR001 ? humanized PD-1 melanoma
Pembrolizumab Keytruda mab humanized PD-1Y melanoma and other cancers
Pemtumomab Theragyn ? mouse MUC1 cancer
Perakizumab[73] mab humanized IL 17A arthritis
Pertuzumab Omnitarg mab humanized HER2/neuY cancer
Pexelizumab[77] scFv humanized C5 reduction of side effects of cardiac surgery
Pidilizumab mab humanized PD-1 cancer and infectious diseases
Pinatuzumab vedotin[30] mab humanized CD22 cancer
Pintumomab mab mouse adenocarcinoma antigen adenocarcinoma (imaging)
Placulumab mab human human TNF pain and inflammatory diseases
Plozalizumab[7] mab humanized CCR2 diabetic nephropathy and arteriovenous graft patency
Pogalizumab[33] mab humanized TNFR superfamily member 4 ?
Polatuzumab vedotin[30] mab humanized CD79B diffuse large B-cell lymphoma
Ponezumab mab humanized human beta-amyloid Alzheimer's disease
Porgaviximab[19] mab chimeric Zaire ebolavirus glycoprotein Ebola virus disease
Prasinezumab[6] mab humanized NACP Parkinson's disease
Prezalizumab[33] mab humanized ICOSL ?
Priliximab mab chimeric CD4 Crohn's disease, multiple sclerosis
Pritoxaximab[30] mab chimeric E. coli shiga toxin type-1 ?
Pritumumab mab human vimentin brain cancer
PRO 140 ? humanized CCR5 HIV infection
Quilizumab[44] mab humanized IGHE asthma
Racotumomab[186] Vaxira mab mouse NGNA gangliosideY non-small cell lung cancer
Radretumab[17] mab human fibronectin extra domain-B cancer
Rafivirumab[51] mab human rabies virus glycoprotein rabies (prophylaxis)
Ralpancizumab mab humanized neural apoptosis-regulated proteinase 1 dyslipidemia
Ramucirumab Cyramza mab human VEGFR2Y solid tumors
Ranevetmab mab veterinary NGF osteoarthritis in dogs
Ranibizumab[5] Lucentis Fab humanized VEGF-AY macular degeneration (wet form)
Raxibacumab[28] mab human anthrax toxin, protective antigenY anthrax (prophylaxis and treatment)
Ravagalimab[4] mab humanized CD40 Crohn's disease
Ravulizumab[6] Ultomiris mab humanized C5Y paroxysmal nocturnal hemaglobinuria, atypical hemolytic uremic syndrome
Refanezumab mab humanized myelin-associated glycoprotein recovery of motor function after stroke
Regavirumab mab human cytomegalovirus glycoprotein B cytomegalovirus infection
Relatlimab mab human LAG3 melanoma
Remtolumab[14] mab human interleukin 17 alpha, TNF ?
Reslizumab[77] Cinqair mab humanized IL-5Y inflammations of the airways, skin and gastrointestinal tract
Rilotumumab mab human HGF solid tumors
Rinucumab mab human platelet-derived growth factor receptor beta neovascular age-related macular degeneration
Risankizumab[7] Skyrizi mab humanized IL23AY Crohn's disease, psoriasis, psoriatic arthritis, and asthma
Rituximab MabThera, Rituxan mab chimeric CD20Y lymphomas, leukemias, some autoimmune disorders
Rivabazumab pegol[7] mab humanized Pseudomonas aeruginosa type III secretion system ?
Robatumumab mab human IGF-1 receptor (CD221) cancer
Rmab RabiShield ? human rabies virus G glycoproteinY post-exposure prophylaxis of rabies
Roledumab[103] mab human RHD Rh disease
Romilkimab[4] mab chimeric/humanized interleukin 13 ?
Romosozumab Evenity mab humanized sclerostinY osteoporosis
Rontalizumab mab humanized IFN-α systemic lupus erythematosus
Rosmantuzumab mab humanized root plate-specific spondin 3 cancer
Rovalpituzumab tesirine[7] mab humanized DLL3 small cell lung cancer
Rovelizumab LeukArrest mab humanized CD11, CD18Y haemorrhagic shock etc.
Rozanolixizumab[14] mab chimeric/humanized FCGRT ?
Ruplizumab[9] Antova mab humanized CD154 (CD40L)Y rheumatic diseases
SA237 ? humanized IL-6R neuromyelitis optica and neuromyelitis optica spectrum disorders
Sacituzumab govitecan mab humanized TROP-2 triple-negative breast cancer
Samalizumab mab humanized CD200 cancer
Samrotamab vedotin[4] mab chimeric/humanized LRRC15 cancer
Sarilumab Kevzara mab human IL6Y rheumatoid arthritis, ankylosing spondylitis
Satralizumab mab humanized IL6 receptor neuromyelitis optica
Satumomab pendetide mab mouse TAG-72 cancer (diagnosis)
Secukinumab Cosentyx mab human IL 17AY uveitis, rheumatoid arthritis psoriasis
Selicrelumab[19] mab human CD40 ?
Seribantumab[30] mab human ERBB3 (HER3) cancer
Setoxaximab[30] mab chimeric E. coli shiga toxin type-2 ?
Setrusumab[6] mab human SOST ?
Sevirumab ? human cytomegalovirus cytomegalovirus infection
Sibrotuzumab mab humanized FAP cancer
SGN-CD19A mab humanized CD19 acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SHP647 ? human mucosal addressin cell adhesion molecule Crohn's disease
Sifalimumab mab humanized IFN-α SLE, dermatomyositis, polymyositis
Siltuximab Sylvant mab chimeric IL-6Y cancer
Simtuzumab[73] mab humanized LOXL2 fibrosis
Siplizumab[13] mab humanized CD2 psoriasis, graft-versus-host disease (prevention)
Sirtratumab vedotin[6] mab human SLITRK6 cancer
Sirukumab mab human IL-6 rheumatoid arthritis
Sofituzumab vedotin mab humanized CA-125 ovarian cancer
Solanezumab[186] mab humanized beta amyloid Alzheimer's disease
Solitomab[44] BiTE mouse EpCAM gastrointestinal, lung, and other cancers
Sonepcizumab[6] ? humanized sphingosine-1-phosphate choroidal and retinal neovascularization
Sontuzumab[191] mab humanized episialin
Spartalizumab[6] mab humanized PDCD1, CD279 melanoma
Stamulumab[67][191] mab human myostatin muscular dystrophy
Sulesomab LeukoScan Fab' mouse NCA-90 (granulocyte antigen) osteomyelitis (imaging)
Suptavumab mab human RSVFR medically attended lower respiratory disease
Sutimlimab[4] mab chimeric/humanized C1s cold agglutinin disease
Suvizumab[118] mab humanized HIV-1 viral infections
Suvratoxumab[19] mab human Staphylococcus aureus alpha toxin nosocomial pneumonia
Tabalumab mab human BAFF B-cell cancers
Tacatuzumab tetraxetan AFP-Cide mab humanized alpha-fetoprotein cancer
Tadocizumab[191] Fab humanized integrin αIIbβ3 percutaneous coronary intervention
Talacotuzumab[6] mab humanized CD123 ?
Talizumab mab humanized IgE allergic reaction
Tamtuvetmab[33] Tactress mab veterinary CD52
Tanezumab[51] mab humanized NGF pain
Taplitumomab paptox[88] mab mouse CD19date=November 2009}}
Tarextumab mab human Notch receptor cancer
Tavolimab mab chimeric/humanized CD134 cancer
Tefibazumab[28] Aurexis mab humanized clumping factor A Staphylococcus aureus infection
Telimomab aritox Fab mouse ?
Telisotuzumab vedotin mab humanized HGFR cancer
Tenatumomab[8] mab mouse tenascin C cancer
Teneliximab[13] mab chimeric CD40 autoimmune diseases and prevention of organ transplant rejection
Teplizumab[42] mab humanized CD3 diabetes mellitus type 1
Tepoditamab[4] mab human dendritic cell-associated lectin 2 cancer
Teprotumumab mab human IGF-1 receptor (CD221) thyroid eye disease
Tesidolumab[16] mab human C5
Tetulomab mab humanized CD37 cancer[7]
Tezepelumab[7] mab human TSLP asthma, atopic dermatitis
TGN1412 ? humanized CD28 chronic lymphocytic leukemia, rheumatoid arthritis
Tibulizumab[6] mab humanized BAFF autoimmune disorders
Tildrakizumab Ilumya mab humanized IL23Y immunologically mediated inflammatory disorders
Tigatuzumab[8] mab humanized TRAIL-R2 cancer
Timigutuzumab[19] mab humanized HER2 cancer
Timolumab[33] mab human AOC3
Tiragotumab[6] mab human TIGIT cancer
Tislelizumab[6] mab humanized PCDC1, CD279 non-small cell lung cancer
Tisotumab vedotin[7] mab human coagulation factor IIIrelapsed or refractory cervical cancer[8]
TNX-650 ? humanized IL-13 Hodgkin's lymphoma
Tocilizumab[5] Actemra, RoActemra mab humanized IL-6 receptorY rheumatoid arthritis
Tomuzotuximab[19] mab humanized EGFR, HER1 cancer
Toralizumab[13] mab humanized CD154 (CD40L) rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab[3] mab human Staphylococcus aureus
Tositumomab Bexxar ? mouse CD20Y follicular lymphoma
Tovetumab mab human PDGFRA cancer
Tralokinumab mab human IL-13 asthma, atopic dermatitis
Trastuzumab Herceptin mab humanized HER2/neuY breast cancer
Trastuzumab emtansine Kadcyla mab humanized HER2/neuY breast cancer
TRBS07[9] Ektomab 3funct ? GD2 ganglioside melanoma
Tregalizumab[17] mab humanized CD4
Tremelimumab mab human CTLA-4 non-small cell lung, head & neck, urothelial cancer
Trevogrumab mab human growth differentiation factor 8 muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin[67][191] mab humanized EpCAM cancer
Tuvirumab ? human hepatitis B virus chronic hepatitis B
Ublituximab[17] mab chimeric MS4A1 multiple sclerosis, chronic lymphocytic leukemia
Ulocuplumab mab human CXCR4 (CD184) hematologic malignancies
Urelumab mab human 4-1BB (CD137) cancer etc.
Urtoxazumab[5] mab humanized Escherichia coli diarrhoea caused by E. coli
Ustekinumab[51] Stelara mab human IL-12, IL-23Y multiple sclerosis, psoriasis, psoriatic arthritis
Utomilumab[35] mab human 4-1BB (CD137) diffuse large B-cell lymphoma
Vadastuximab talirine[7] mab chimeric CD33 Acute myeloid leukemia
Vanalimab[4] mab humanized CD40 ?
Vandortuzumab vedotin[16] mab humanized STEAP1 cancer
Vantictumab mab human Frizzled receptor cancer
Vanucizumab[22] mab humanized angiopoietin 2 cancer
Vapaliximab[13] mab chimeric AOC3 (VAP-1)
Varisacumab[19] mab human VEGF-A angiogenesis
Varlilumab mab human CD27 solid tumors and hematologic malignancies
Vatelizumab[34] mab humanized ITGA2 (CD49b)
Vedolizumab Entyvio mab humanized integrin α4β7Y Crohn's disease, ulcerative colitis
Veltuzumab[8] mab humanized CD20 non-Hodgkin's lymphoma
Vepalimomab mab mouse AOC3 (VAP-1) inflammation
Vesencumab[17] mab human NRP1 solid malignancies
Visilizumab[88] Nuvion mab humanized CD3 Crohn's disease, ulcerative colitis
Vobarilizumab[33] scFv humanized IL6R inflammatory autoimmune diseases
Volociximab[20] mab chimeric integrin α5β1 solid tumors
Vonlerolizumab mab humanized CD134 cancer
Vopratelimab[4] mab humanized CD278, aka ICOS ?
Vorsetuzumab mafodotin mab humanized CD70 cancer
Votumumab HumaSPECT mab human tumor antigen CTAA16.88 colorectal tumors
Vunakizumab[14] mab humanized interleukin 17 alpha ?
Xentuzumab[33] mab humanized IGF1, IGF2?
XMAB-5574 ? humanized CD19 diffuse large B-cell lymphoma
Zalutumumab[20] HuMax-EGFr mab human EGFR squamous cell carcinoma of the head and neck
Zanolimumab[5] HuMax-CD4 mab human CD4 rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab[73] mab chimeric HER1 cancer
Zenocutuzumab[6] mab humanized ERBB3, HER3 cancer
Ziralimumab[88] mab human CD147 (basigin) ?
Zolbetuximab[6] (=IMAB362, Claudiximab) mab chimeric Claudin 18 Isoform 2 gastric cancer, gastrointestinal adenocarcinoma and pancreatic cancer
Zolimomab aritox mab mouse CD5 systemic lupus erythematosus, graft-versus-host disease

References

1. ^{{cite journal | last1=Buhmann| first1=R | title=Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion| journal=Bone Marrow Transplantation | volume=43 | issue=5| pages=383–397 | year=2008 | url=http://www.nature.com/bmt/journal/v43/n5/full/bmt2008323a.html | pmid=18850012 | last2=Simoes | first2=B | last3=Stanglmaier | first3=M | last4=Yang | first4=T | last5=Faltin | first5=M | last6=Bund | first6=D | last7=Lindhofer | first7=H | last8=Kolb | first8=HJ | doi=10.1038/bmt.2008.323|display-authors=etal}}
2. ^{{cite journal | last1=Boehrer| first1=S | title=Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms | journal=Anti-Cancer Drugs |volume=12 | issue=10| pages=3085–3091 | year=2011 | doi=10.1097/CAD.0b013e328344887f | pmid=21637160 | last2=Schroeder | first2=Petra | last3=Mueller | first3=Tina | last4=Atz | first4=Judith | last5=Chow | first5=Kai Uwe|display-authors=etal}}
3. ^{{Cite web | url=http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html | title=Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®}}
4. ^1 {{cite news |last=Guthrie|first=Arlo|title=Zoetis launches breakthrough treatment for canine atopic dermatitis |url=https://www.vetnurse.co.uk/b/veterinary-nursing-news/archive/2017/06/27/zoetis-launches-breakthrough-treatment-for-canine-atopic-dermatitis.aspx |accessdate=2018-07-06 |work=VetNurse News |date=27 June 2017}}
5. ^{{Cite journal | doi=10.1056/NEJMoa1606490| pmid=28249150|title = Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis| journal=New England Journal of Medicine| volume=376| issue=9| pages=826–835|year = 2017|last1 = Ruzicka|first1 = Thomas| last2=Hanifin| first2=Jon M.| last3=Furue| first3=Masutaka| last4=Pulka| first4=Grazyna| last5=Mlynarczyk| first5=Izabela| last6=Wollenberg| first6=Andreas| last7=Galus| first7=Ryszard| last8=Etoh| first8=Takafumi| last9=Mihara| first9=Ryosuke| last10=Yoshida| first10=Hiroki| last11=Stewart| first11=Jonathan| last12=Kabashima| first12=Kenji| author13=XCIMA Study Group}}
6. ^{{Cite journal| doi = 10.1002/jcp.21588| title = Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization| year = 2009| last1 = Xie | first1 = B.| last2 = Shen | first2 = J.| last3 = Dong | first3 = A.| last4 = Rashid | first4 = A.| last5 = Stoller| pmc = 2905312 | first5 = G.| last6 = Campochiaro | first6 = P. A.| journal = Journal of Cellular Physiology| volume = 218| pages = 192–198| pmid = 18781584| issue = 1}}
7. ^{{Cite journal |author1=Jostein Dahle |author2=Ada H. V. Repetto-Llamazares |author3=Camilla S. Mollatt |author4=Katrine B. Melhus |author5=Oyvind S. Bruland |author6=Arne Kolstad |author7=Roy H. Larsen | title = Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma | journal = Anticancer Research | volume = 33 | issue = 1 | pages = 85–95 | date= January 2013 | pmid = 23267131}}
8. ^{{Cite journal|last=Wright|first=Rob|date=13 February 2018|title=Seattle Genetics Legacy Of Partnering|url=https://www.lifescienceleader.com/doc/seattle-genetics-legacy-of-partnering-0001|journal=Life Science Leader|volume=|at=Beyond The Printed Page|access-date=22 February 2018|via=}}
9. ^{{cite journal | last1=Ruf| first1=P | title=Two new trifunctional antibodies for the therapy of human malignant melanoma | journal=International Journal of Cancer | volume=108 | pages=725–732 | year=2004 | pmid=14696099 | doi=10.1002/ijc.11630 | last2=Jäger | first2=M | last3=Ellwart | first3=J | last4=Wosch | first4=S | last5=Kusterer | first5=E | last6=Lindhofer | first6=H | issue=5|display-authors=etal}}
10. ^1 2 3 4 5 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56 | journal = WHO Drug Information | volume = 20 | issue = 3 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf | format=PDF}}
11. ^1 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66 | journal = WHO Drug Information | volume = 5 | issue = 4 | year = 1991 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf | format=PDF}}
12. ^1 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77 | journal = WHO Drug Information | volume = 11 | issue = 2 | year = 1997 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf | format=PDF}}
13. ^1 2 3 4 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83 | journal = WHO Drug Information | volume = 14 | issue = 2 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf | format=PDF}}
14. ^1 2 3 4 5 6 7 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84 | journal = WHO Drug Information | volume = 14 | issue = 4 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | format=PDF}}
15. ^1 2 3 4 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85 | journal = WHO Drug Information | volume = 15 | issue = 2 | year = 2001 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | format=PDF}}
16. ^1 2 3 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86 | journal = WHO Drug Information | volume = 16 | issue = 12 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf | format=PDF}}
17. ^1 2 3 4 5 6 7 8 9 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87 | journal = WHO Drug Information | volume = 16 | issue = 2 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf | format=PDF}}
18. ^1 2 3 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88 | journal = WHO Drug Information | volume = 17 | issue = 1 | year = 2003 | url = http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf | format=PDF}}
19. ^1 2 3 4 5 6 7 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | format=PDF}}
20. ^1 2 3 4 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91 | journal = WHO Drug Information | volume = 18 | issue = 2 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf | format=PDF}}
21. ^1 2 3 4 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92 | journal = WHO Drug Information | volume = 18 | issue = 4 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf | format=PDF}}
22. ^1 2 3 4 5 6 7 8 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93 | journal = WHO Drug Information | volume = 19 | issue = 2 | year = 2008 | url = http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf | format=PDF}}
23. ^1 2 3 4 5 6 7 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94 | journal = WHO Drug Information | volume = 19 | issue = 4 | year = 2005 | url = http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf | format=PDF}}
24. ^1 2 3 4 5 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95 | journal = WHO Drug Information | volume = 20 | issue = 2 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf | format=PDF}}
25. ^1 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96 | journal = WHO Drug Information | volume = 20 | issue = 4 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf | format=PDF}}
26. ^1 2 3 4 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97 | journal = WHO Drug Information | volume = 21 | issue = 2 | year = 2007 | url = http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf | format=PDF}}
27. ^1 2 3 4 5 6 7 8 9 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98 | journal = WHO Drug Information | volume = 21 | issue = 4 | year = 2007 | url = http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf | format=PDF}}
28. ^1 2 3 4 5 6 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99 | journal = WHO Drug Information | volume = 22 | issue = 2 | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf | format=PDF}}
29. ^1 2 3 4 5 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy) | journal = WHO Drug Information | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf | format=PDF}}
30. ^1 2 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101 | journal = WHO Drug Information | volume = 23 | issue = 2 | year = 2009 | url = http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf | format=PDF}}
31. ^1 2 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102 | journal = WHO Drug Information | volume = 23 | issue = 4 | year = 2009 | url = http://www.who.int/medicines/services/inn/FINAL_PL102.pdf | format=PDF}}
32. ^1 2 3 4 5 6 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}
33. ^1 2 3 4 5 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format=PDF}}
34. ^1 2 3 4 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}}
35. ^1 2 3 4 5 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 | journal = WHO Drug Information | volume = 25 | issue = 4 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf | format=PDF}}
36. ^1 2 3 4 5 6 7 8 9 10 11 12 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}}
37. ^1 2 3 4 5 6 7 8 9 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf | format=PDF}}
38. ^1 2 3 4 5 6 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109 | journal = WHO Drug Information | volume = 27 | issue = 2 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL109.pdf | format=PDF}}
39. ^1 2 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 | journal = WHO Drug Information | volume = 27 | issue = 4 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL110.pdf | format=PDF}}
40. ^1 2 3 4 5 6 7 8 9 10 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 | journal = WHO Drug Information | volume = 28 | issue = 2 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf | format=PDF}}
41. ^1 2 3 4 5 6 7 8 9 10 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112 | journal = WHO Drug Information | volume = 28 | issue = 4 | year = 2014 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL112.pdf | format=PDF}}
42. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113 | journal = WHO Drug Information | volume = 29 | issue = 2 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf | format=PDF}}
43. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 | journal = WHO Drug Information | volume = 29 | issue = 4 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf | format=PDF}}
44. ^1 2 3 4 5 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115 | journal = WHO Drug Information | volume = 30 | issue = 2 | year = 2016 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf | format=PDF}}
45. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116 | journal = WHO Drug Information | volume = 30 | issue = 4 | year = 2016 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL116.pdf | format=PDF}}
46. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117 | journal = WHO Drug Information | volume = 31 | issue = 2 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf | format=PDF}}
47. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118 | journal = WHO Drug Information | volume = 31 | issue = 4 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL118.pdf | format=PDF}}
48. ^1 2 3 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119 | journal = WHO Drug Information | volume = 32 | issue = 2 | year = 2018 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL119.pdf | format=PDF}}
49. ^1 2 3 4 5 6 7 8 9 10 11 12 {{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77 | journal = WHO Drug Information | volume = 31 | issue = 1 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/RL77.pdf | format=PDF}}
50. ^1 {{ClinicalTrialsGov|NCT00883896|Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis}}
51. ^1 {{ClinicalTrialsGov|NCT00563524|Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis}}
52. ^1 {{ClinicalTrialsGov|NCT00537381|A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer}}
53. ^1 {{ClinicalTrialsGov|NCT00246012|A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma}}
54. ^1 {{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire|title=BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody|date=10 November 2009|publisher=Genetic Engineering & Biotechnology News}}
55. ^1 {{cite web|url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing |year=2008 |publisher=Wyeth |accessdate=November 19, 2008 |archiveurl=https://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archivedate=June 12, 2008 |deadurl=yes |df= }}
56. ^1 NCI Drug Dictionary: Glemtumumab vedotin
57. ^1 {{cite web|url=https://www.sec.gov/Archives/edgar/data/1082554/000104746911001229/a2202121z10-k.htm#da77001_item_1._business|title=United Therapeutics 10-K report|accessdate=5 November 2011}}
[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57]
}}{{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}{{Monoclonals for immune system}}{{Monoclonals for infectious disease and toxins}}{{Monoclonals for tumors}}{{Engineered antibodies}}

3 : Drug-related lists|Monoclonal antibodies|Immunology
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/14 2:30:53